NCT01925950View on ClinicalTrials.gov

Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Chronic Gastrointestinal Graft vs Host Disease
Interventions
DRUG

orBec

DRUG

Placebo

Trial Locations (3)

14263

Roswell Park Cancer Institute, Buffalo

37232

Vanderbilt-Ingram Cancer Center, Nashville

07601

John Theurer Cancer Center, Hackensack

Sponsors

Lead Sponsor

Soligenix
All Listed Sponsors
lead

Soligenix

INDUSTRY

NCT01925950 - Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD) | Biotech Hunter | Biotech Hunter